Thomas Wolter

Thomas works primarily in the biopharma sector, mainly with big pharma companies undertaking drug discovery and development. He advises on all stages of a drug’s lifecycle, from initial discovery through clinical trials to regulatory approval. Working closely with in-house IP teams and scientists, he has extensive experience of the prosecution and European opposition and appeal procedures as well as SPCs. Thomas was involved in litigation and/or opposition proceedings concerning dasatinib, nivolumab, ipilimumab, eptinezumab, abatacept, belatacept, crenezumab, etanercept, calcipotriol, levofloxacin, and others.

Areas of Expertise

• Immunology and immuno-oncology
• Therapeutic antibodies
• Fusion proteins
• Human blood plasma products
• Iron carbohydrate complexes
• Production and formulation of biologics
• Special drug forms, e.g., polymorphs and enantiomers
• Combination therapies
• Patent term extension (PTE) and supplementary protection certificates (SPCs)

Clients

Thomas works mainly with biopharma companies including large US and European multinationals, SME's and small biotechs.

Background

Thomas has a double Master’s degree in chemistry and biology from Ruhr-Universität Bochum, Germany, and a PhD from Université Louis Pasteur Strasbourg, France.

He qualified as German and European Patent Attorney in 1999. He has practiced at a German patent law firm before joining Mewburn Ellis in 2020.